PMGC (ELAB) Competitors $6.34 +0.93 (+17.19%) Closing price 04:00 PM EasternExtended Trading$6.11 -0.23 (-3.63%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock ELAB vs. SNPX, APRE, VYNE, CELZ, ERNA, CSCI, CAPS, BMRA, PRTG, and HCWBShould you be buying PMGC stock or one of its competitors? The main competitors of PMGC include Synaptogenix (SNPX), Aprea Therapeutics (APRE), VYNE Therapeutics (VYNE), Creative Medical Technology (CELZ), Ernexa Therapeutics (ERNA), COSCIENS Biopharma (CSCI), Capstone Therapeutics (CAPS), Biomerica (BMRA), Portage Biotech (PRTG), and HCW Biologics (HCWB). These companies are all part of the "pharmaceutical products" industry. PMGC vs. Its Competitors Synaptogenix Aprea Therapeutics VYNE Therapeutics Creative Medical Technology Ernexa Therapeutics COSCIENS Biopharma Capstone Therapeutics Biomerica Portage Biotech HCW Biologics Synaptogenix (NASDAQ:SNPX) and PMGC (NASDAQ:ELAB) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership. Does the media prefer SNPX or ELAB? In the previous week, Synaptogenix's average media sentiment score of 0.00 equaled PMGC'saverage media sentiment score. Company Overall Sentiment Synaptogenix Neutral PMGC Neutral Do analysts prefer SNPX or ELAB? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00PMGC 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Do insiders & institutionals have more ownership in SNPX or ELAB? 10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 22.2% of PMGC shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by company insiders. Comparatively, 0.2% of PMGC shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better earnings & valuation, SNPX or ELAB? PMGC has higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than PMGC, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynaptogenixN/AN/A-$12.77M-$10.08-0.76PMGC$1.71M1.56-$6.25M-$433.87-0.01 Is SNPX or ELAB more profitable? PMGC's return on equity of -62.73% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets SynaptogenixN/A -115.28% -58.31% PMGC N/A -62.73%-52.83% Which has more volatility & risk, SNPX or ELAB? Synaptogenix has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, PMGC has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500. SummaryPMGC beats Synaptogenix on 7 of the 10 factors compared between the two stocks. Get PMGC News Delivered to You Automatically Sign up to receive the latest news and ratings for ELAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELAB vs. The Competition Export to ExcelMetricPMGCDIVERSIFIED OPS IndustryMulti-Sector SectorNASDAQ ExchangeMarket Cap$2.66M$16.45B$15.07B$10.53BDividend YieldN/A3.45%3.31%4.67%P/E Ratio-0.0112.1510.1026.86Price / Sales1.568.837.30185.42Price / CashN/A46.9443.5931.10Price / Book0.162.422.136.72Net Income-$6.25M$953.12M$923.61M$276.44M7 Day Performance19.85%-0.70%-0.49%3.13%1 Month Performance39.96%5.36%4.78%10.21%1 Year Performance-98.77%12.01%10.16%40.35% PMGC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELABPMGC1.0407 of 5 stars$6.34+17.2%N/A-99.0%$2.66M$1.71M-0.0118Gap UpHigh Trading VolumeSNPXSynaptogenixN/A$6.28+7.4%N/A+121.0%$8.73MN/A-0.624APREAprea Therapeutics2.2355 of 5 stars$1.48-2.3%$15.50+950.8%-42.9%$8.60M$1.50M-0.647Positive NewsVYNEVYNE Therapeutics2.6075 of 5 stars$0.34+1.8%$6.25+1,765.7%-80.9%$8.53M$500K-0.3730News CoverageGap UpCELZCreative Medical Technology0.8399 of 5 stars$3.29-0.6%N/A+12.7%$8.49M$10K-1.035News CoveragePositive NewsERNAErnexa Therapeutics0.6495 of 5 stars$1.10-6.4%N/A-91.5%$8.40M$488K-0.1310CSCICOSCIENS BiopharmaN/A$2.61-15.3%N/A-29.5%$8.29M$9.44M-0.4320Gap DownHigh Trading VolumeCAPSCapstone TherapeuticsN/A$1.31-0.8%N/AN/A$8.27M$44.88M0.0038News CoverageBMRABiomerica0.1656 of 5 stars$2.83-0.7%N/A+12.7%$8.02M$5.31M-1.2260News CoverageShort Interest ↑PRTGPortage BiotechN/A$7.63+9.6%N/A+38.5%$8.01MN/A-0.186Gap UpHigh Trading VolumeHCWBHCW Biologics1.8168 of 5 stars$3.70-3.6%$35.00+845.9%-77.6%$7.96M$832.84K-0.2640Positive NewsGap Down Related Companies and Tools Related Companies SNPX Alternatives APRE Alternatives VYNE Alternatives CELZ Alternatives ERNA Alternatives CSCI Alternatives CAPS Alternatives BMRA Alternatives PRTG Alternatives HCWB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELAB) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMGC Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PMGC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
